Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: A new model for studying the functions of the P450 system

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 40-47

  Finn, Robert D ^a   McLaren, Aileen W ^a   Carrie, Dianne ^a   Henderson, Colin J ^a   Wolf, C Roland ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3 METHYLCHOLANTHRENE; BETA NAPHTHOFLAVONE; CRE RECOMBINASE; CYTOCHROME P450; CYTOCHROME P450 1A1; LIPID; OXIDOREDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFICACY; ENZYME METABOLISM; FATTY LIVER; GASTROINTESTINAL TRACT; GENE DELETION; GENE EXPRESSION; HOMEOSTASIS; LIPID STORAGE; LIVER; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICOKINETICS;

ANIMALS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL TRACT; INTEGRASES; LIGANDS; LIVER; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); RECEPTORS, ARYL HYDROCARBON; TETRACHLORODIBENZODIOXIN;

EID: 34250721635     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.121780     Document Type: Article

References (39)

1. Albanese C, Hulit J, Sakamaki T, and Pestell RG (2002) Recent advances in inducible expression in transgenic mice. Semin Cell Dev Biol 13:129-141.
2. Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH, et al. (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD-(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65:2644-2652.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Campbell SJ, Carlotti F, Hall PA, Clark AJ, and Wolf CR (1996) Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 109:2619- 2625.
5. Colby HD, Abbott B, Cachovic M, Debolt KM, and Mico BA (1995) Inactivation of adrenal cytochromes P450 by 1-aminobenzotriazole. Divergence of in vivo and in vitro actions. Biochem Pharmacol 49:1057-1062.
6. Dey A, Jones JE, and Nebert DW (1999) Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem Pharmacol 58:525-537.
7. Emoto C, Murase S, Sawada Y, Jones BC, and Iwasaki K (2003) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18:287-295.
8. Fontana E, Dansette PM, and Poli SM (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413-454.
9. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, et al. (1992) Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281:359-368.
10. Gossen M and Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89:5547-5551.
11. Gu J, Chen CS, Wei Y, Fang C, Xie F, Kannan K, Yang W, Waxman DJ, and Ding X (2007) A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J Pharmacol Exp Ther 321:9-17.
12. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, Yang W, Zhang L, and Ding X (2003) Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 278:25895-25901.
13. Hayashi S and McMahon AP (2002) Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/ inactivation in the mouse. Dev Biol 244:305-318.
14. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, and Wolf CR (2003a) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278:13480-13486.
15. Henderson CJ, Otto DM, McLaren AW, Carrie D, and Wolf CR (2003b) Knockout mice in xenobiotic metabolism. Drug Metab Rev 35:385-392.
16. Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, Sansom OJ, and Winton DJ (2004) Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 126:1236-1246.
17. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, and Mullins JJ (2001) Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 276:36727-36733.
18. Ko MS, Takahashi N, Sugiyama N, and Takano T (1989) An auto-inducible vector conferring high glucocorticoid inducibility upon stable transformant cells. Gene 84:383-389.
19. Li-Masters T and Morgan ET (2001) Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. Drug Metab Dispos 29:252-257.
20. Meehan RR, Forrester LM, Stevenson K, Hastie ND, Buchmann A, Kunz HW, and Wolf CR (1988) Regulation of phenobarbital-inducible cytochrome P-450s in rat and mouse liver following dexamethasone administration and hypophysectomy. Biochem J 254:789-797.
21. Mugford CA, Mortillo M, Mico BA, and Tarloff JB (1992) 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Fundam Appl Toxicol 19:43-49.
22. Nekvindová J, Masek V, Veinlichova A, Anzenbacherova E, Anzenbacher P, Zidek Z, and Holy A (2006) Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. Xenobiotica 36:1165-1177.
23. Ortiz de Montellano PR, and Mathews JM (1981) Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne-protoporphyrin IX adduct. Biochem J 195:761-764.
24. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, and Wolf CR (2005) Role of hepatic cytochrome P450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome P450 reductase null mouse. Cancer Res 65:4211-4217.
25. Rushmore TH and Kong AN (2002) Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3:481-490.
26. Schweinfest CW, Jorcyk CL, Fujiwara S, and Papas TS (1988) A heat-shock-inducible eukaryotic expression vector. Gene 71:207-210.
27. Smith GC, Tew DG, and Wolf CR (1994) Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc Natl Acad Sci U S A 91: 8710-8714.
28. Soltis M and Colby HD (1998) Inhibition of testicular steroid metabolism by administration of 1-aminobenzotriazole to rats. Pharmacology 56:51-56.
29. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98:3369-3374.
30. Strelevitz TJ, Foti RS, and Fisher MB (2006) In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334-1341.
31. Thörn M, Finnstrom N, Lundgren S, Rane A, and Loof L (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60:54-60.
32. Turpeinen M, Raunio H, and Pelkonen O (2006) The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 7:705-714.
33. Wang XJ, Chamberlain M, Vassieva O, Henderson CJ, and Wolf CR (2005) Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice. Biochem J 388:857-867.
34. Wei P, Zhang J, Egan-Hafley M, Liang S, and Moore DD (2000) The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407:920-923.
35. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, and Haefeli WE (2006) Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 35:340-344.
36. Weng Y, Dirusso CC, Reilly AA, Black PN, and Ding X (2005) Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene: mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype. J Biol Chem 280:31686-31698.
37. Wu L, Gu J, Cui H, Zhang QY, Behr M, Fang C, Weng Y, Kluetzman K, Swiatek PJ, Yang W, et al. (2005) Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 312:35-43.
38. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, and Evans RM (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439.
39. Zhang QY, Dunbar D, and Kaminsky LS (2003) Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31:1346-1351.